BMB-101, an oral serotonin agonist being developed by Bright Minds Biosciences for the treatment of Dravet syndrome and…
Articles by Margarida Maia, PhD
Up to 1 in 4 people with hard-to-treat epilepsy, including those with Dravet syndrome, were found to stop taking…
More severe epilepsy and greater behavioral challenges predict worse health-related quality of life (HRQoL) up to 10 years later in…
Biocodex has chosen Pantherx Rare specialty pharmacy to be the sole U.S. distributor of Diacomit (stiripentol), an…
Treatment with soticlestat, an inhibitor of cholesterol turnover in the brain, protected against fever-induced seizures in two mouse models of…
Pharmaceutical giant UCB has agreed to buy Zogenix, the developer of Fintepla (fenfluramine), an oral add-on medicine that…
Ovid Therapeutics has closed an agreement under which Takeda Pharmaceuticals will secure global rights to develop and market the…